The Most Surprising Cdmo Industry Statistics in 2023

Facts about this Market Data Report

IconJournalist involved: 2
IconCited by: 123
IconStatistics researched: 40

Highlights: The Most Important Cdmo Industry Statistics

Table of Contents

In a rapidly evolving pharmaceutical landscape, the Contract Development and Manufacturing Organization (CDMO) industry remains integral and increasingly influential for its marked contribution to healthcare and medicine. Helping to shed light on this vital sector, this blog post aims to present an in-depth analysis of the latest CDMO Industry statistics. We will delve into the numbers, uncovering the trends, growth projections, and the potential impacts they portend for the industry at large. Whether you're an investor seeking opportunities, a professional involved in the pharmaceutical industry, or simply staying ahead of the curve, this overview will provide a greater understanding of the market dynamics driving the CDMO industry.

The Latest Cdmo Industry Statistics Unveiled

The global CDMO (Contract Development and Manufacturing Organizations) Industry market is projected to reach a size of 278 billion dollars by 2024.

Delving into the riveting projections for the global CDMO Industry, one cannot turn a blind eye to the tantalizing prediction of it reaching a monumental valuation of $278 billion by 2024. Indeed, this statistical gem is a vital cog in understanding the scope and scale of this rapidly evolving industry. It sets the trajectory of the industry's growth, revealing the sheer potential and economic gains it's poised to deliver in the near future. Such a projection furnishes readers with compelling insight, acting as a barometer for gauging industry trends, growth drivers, and investment prospects, helping them to form an informed perspective about the thriving CDMO landscape.

The CDMO industry is expected to grow at a CAGR (Compound Annual Growth Rate) of 12.4% from 2020 to 2026.

Spotlighting this impressive statistic unveils significant insights and propels the narrative of the blog post forward. The projected 12.4% CAGR for the CDMO industry from 2020 to 2026 represents vibrant growth and expansion, adding a layer of deep understanding about the transformative change poised to sweep this industry. To entrepreneurs, investors, and stakeholders, this paints a picture of potent market opportunities and spaces for innovation. For those contemplating an entrance into the industry or those who are already integral parts, this forecast signals a thriving and dynamic trajectory conveying an environment rich with potential and promise.

The North American region holds the largest share in the CDMO market with about 44.3% as of 2019.

As we delve into the world of CDMO Industry Statistics, one cannot simply overlook the commanding presence of the North American region. Standing tall with a whopping 44.3% share as of 2019, North America indisputably holds the leading position in the CDMO market. This scale of dominance not only delineates the region's substantial influence but also signifies its major role in shaping the trends and trajectories of the global CDMO industry.

Europe accounts for the second largest share in the global CDMO market with 33.6%.

Shining a spotlight on Europe's notable command of a potent 33.6% in the global CDMO market dramatically underscores the pivotal role this continent plays in this sector. Seen through the lens of blog post on CDMO industry statistics, it offers a compelling narrative of Europe's significant contribution and consequential influence in shaping the contours of this global market. The potent gravity of the statistic not only highlights the strategic importance of Europe but also initiates an interesting thought process regarding the regional dynamics and competitive landscape within the CDMO industry.

The bulk drug substance segment dominates the CDMO market with a 57.6% share in 2020.

Exploring the magnitude of the CDMO industry, it is striking to observe how the bulk drug substance segment carves an overwhelming proportion of the market, securing a 57.6% share in 2020. Such a figure paints a vivid picture of market dynamics, elucidating where the dominant industry force resides. This highlights the competitive landscape within the industry and underscores the potential strategies for investment, growth, and business focus. When delving into the crux of CDMO industry statistics, this vivid pictorial presentation of the market share becomes quite influential.

The API manufacturing market is the largest segment in the CDMO industry, contributing 53% of the total revenue.

Illuminating the landscape of the CDMO industry with revealing statistics, the 53% revenue contribution of the API manufacturing market indisputably highlights its dominant role. Establishing itself as the colossal segment within the industry, it acts as a key driver in shaping market trends, investment decisions, and strategic development. This signifies potential growth areas for businesses in the CDMO sector and sets the API manufacturing market as a benchmark for comparison. The data not only describes the current state of affairs but also, intriguingly, hints at the future directions of the CDMO industry.

Biologics are forecasted to be the fastest growing segment in the CDMO industry with a CAGR of 15.4% from 2020 to 2026.

Delving deeper into the realm of CDMO (Contract Development and Manufacturing Organization) Industry statistics, one cannot overlook the fact that Biologics stand at the dawn of an explosive growth. With the projected CAGR (Compound Annual Growth Rate) of 15.4% from 2020 to 2026, it undoubtedly magnifies the impact these biological products are primed to create on this industry. This potentially transformative growth highlights the robust acceleration within the biologics segment, signifying a pivotal shift from traditional pharmaceuticals. Therefore, stakeholders and potential investors should be watchful of this trend, as it could open up new horizons for innovation, investment, and growth within the CDMO industry.

72% of pharmaceutical companies presently outsource at least part of their drug development and manufacturing processes to CDMOs.

Serving as the lifeblood of the blog post on CDMO industry statistics, the noteworthy information that 72% of pharmaceutical companies currently delegate a portion of their drug development and manufacturing assignments to CDMOs plays a significant role. It magnifies the essential symbiosis between pharmaceutical names and these contract development and manufacturing organizations. Not only does this statistic underscore the trust these pharmaceutical companies place in CDMOs, but it also speaks volumes of the industry’s health and potential. Furthermore, it presents a near-real-time snapshot of business models and strategies being employed within the pharmaceutical sector. This prevailing trend of outsourcing paints a vibrant picture of future growth opportunities for CDMOs and stresses their vital part in the wider pharmaceutical spectrum.

Approximately 42% of revenue from the North American CDMO market comes from the biotechnological industry.

Highlighting that nearly half of the revenue from the North American CDMO market is drawn from the biotechnological industry provides an impressive perspective. It underscores the considerable role biotech contributes in powering this sector's financial engine. This piece of data forms a crucial pillar in understanding the market dynamics, helping readers comprehend which area of industry has taken a lead role in the money inflow. It propels the narrative further, inspiring robust discussion and incisive analysis in the context of a blog about CDMO Industry Statistics. Also, it arms potential investors and stakeholders with vital information that can guide decision-making to capitalize on prevailing trends in the market.

The largest CDMO in 2020 was Catalent with a market share of 8%.

Illuminating the landscape of the CDMO industry like a lighthouse in heavy fog, the statistic around Catalent's 8% market share in 2020 offers fertile ground for analysis. It not only set the stage to appreciate Catalent’s dominion over its competitors, but also provides a lens to dissect the inherent competitive dynamics of this sector. Furthermore, it spawns key discussions around market fragmentation, potential for growth, and M&A opportunities while also serving as a crucial yardstick for gauging industry trends and shifts. Just as a compass points north, this data points towards crucial information relevant for any stakeholder looking to understand, participate, or invest in the CDMO industry.

The oncology segment is projected to have the fastest growth in the CDMO market with a CAGR of 14.2% from 2021 to 2027.

In the vibrant tableau of the CDMO industry panorama, the oncology segment takes center stage. Poised to skyrocket with a CAGR of 14.2% from 2021 to 2027, it's lighting the path toward an exciting era of rapid expansion and significant market share. This projection has monumental implications for stakeholders in the industry. It pinpoints the oncology segment as a hotbed of opportunity and potential profitability. Highlighting areas of accelerated growth, such as this, equips industry participants with valuable insights to drive strategic decision-making, potentially shaping their investments, partnerships, and development initiatives for that period. This paints a promising picture for not only the growth of the oncology segment but also the overall upward trajectory of the CDMO industry.

The oral formulations segment held a market share of nearly 60% in the pharmaceutical contract manufacturing market in 2020.

Delving into the bustling world of CDMO (Contract Development and Manufacturing Organization) Industry Statistics, we stumble upon an intriguing pattern - 'the oral formulations segment grasped almost 60% of the pharmaceutical contract manufacturing market' within the 2020 timeline. This compelling statistic commands attention as it underlines the dominance of oral formulations in this specific industry. It sketches a clear picture for stakeholders of where majority consumer preferences lie, giving them deep insights into how resources might be best allocated for optimal returns. Moreover, it sends a resounding message to new entrants about which segment to focus on, and it acts as a harbinger for the future industry trends, indicating potential areas of growth and innovation. In sum, these figures unveil a state of play that could drive strategic decision-making across all entities venturing into the realm of pharmaceutical contract manufacturing.

The injectables are expected to generate a revenue of around 60 billion USD by 2025 in the CDMO industry.

In crafting a comprehensive vision of the CDMO industry landscape, one cannot overlook the noteworthy projection of the injectables market poised to rake in a striking 60 billion USD by 2025. This figure is far from a mere statistic - it pulses with revelations about the rapidly transforming dynamics of the Contract Development and Manufacturing Organization (CDMO) industry.

Projected revenues of such magnitude instill an understanding of the substantial economic significance and potential profitability of the injectables segment, reflecting its robust growth. This statistic concurrently paints a picture of future opportunities and trends, becoming a beacon for investors, stakeholders, and businesses navigating the industry.

So, as we delve into the nuanced world of CDMO industry statistics, let the drumroll of the 60 billion USD forecast resonate, illuminating the potential of the injectables market and reaffirming its growth trajectory for years to come.

Non-sterile pharmaceutical manufacturing will contribute nearly 70% to pharma’s CDMO outsourcing volume by 2025.

In the ever-evolving orchestra of the CDMO (Contract Development and Manufacturing Organizations) industry, this particular trend strikes a resounding note. Imagine this - by 2025, nearly 70% of pharma's CDMO outsourcing volume will be occupied by non-sterile pharmaceutical manufacturing. This crescendo unveils an electrifying shift in outsourcing trends that could revolutionize the industry's landscape.

Such seismic shift illuminates how CDMOs should strategically pivot their resources to align with this surge. It suggests that companies venturing into non-sterile pharmaceutical manufacturing could be dancing with a golden goose, potentially unlocking significant growth and profitability.

Moreover, it underscores a potential wave of innovation in non-sterile processes, safety protocols, and equipment advancements, birthing cutting-edge solutions that could power the industry's next phase of excellence. Ultimately, this trend paints a profound picture of the future, one where non-sterile pharmaceutical manufacturing takes center stage in the grand performance of the pharma CDMO industry.


The CDMO industry is rapidly growing and is set to change the dynamics of the pharmaceutical sector. With increasing demand and a wealth of promising statistics, it is clear that the CDMO industry offers numerous opportunities for innovative growth and prosperity. Business leaders and investors should remain attentive to this trend and strategically position themselves to capitalize on the immense potential of this evolving industry. The future of pharmaceutical manufacturing looks promising, as the CDMO industry continues to reshape and redefine the market.


0. -

1. -

2. -

3. -

4. -

5. -

6. -

7. -

8. -

Frequently Asked Questions

CDMO stands for Contract Development and Manufacturing Organization. It’s a company that serves other companies in the pharmaceutical industry on contractual basis and provides comprehensive services from drug development through drug manufacturing.
A CDMO helps a pharmaceutical company to streamline its operations and reduce costs. They provide a variety of services such as drug development, formulation development, clinical trial supply, commercial scale manufacturing, and even regulatory support.
The global CDMO market was valued at USD 148.1 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2021 to 2028, according to a report from Grand View Research. Several factors like increasing demand for generic medicines and biologics, operational benefits, expanding pharmaceutical industry, and regulatory shifts are primarily driving the market.
Some of the leading companies in the CDMO industry include Lonza Group, Catalent Inc, Thermo Fisher Scientific, WuXi AppTec, and FAMAR Health Care Services.
The CDMO industry faces several challenges including capacity constraints, complexity in production and strict quality requirements. With the increasing demand for pharmaceutical products, CDMOs must maintain their operational efficiency and keep up with technological advancements. They are also required to comply with stringent regulations which presents a challenge.
How we write these articles

We have not conducted any studies ourselves. Our article provides a summary of all the statistics and studies available at the time of writing. We are solely presenting a summary, not expressing our own opinion. We have collected all statistics within our internal database. In some cases, we use Artificial Intelligence for formulating the statistics. The articles are updated regularly. See our Editorial Guidelines.

Table of Contents

Free Test

Leadership Personality Test

Avatar Group
No credit card | Results in 10 minutes